cid-103
cid-103: developed by 1 company · 2 clinical trials tracked.
cid-103 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could cid-103 → CASI affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (1)
| Company | Phase |
|---|---|
| CASI Pharmaceuticals, Inc (DE) (CASI) | Phase 1 |
Clinical Trials (2)
A 2 Part Dose-escalation Safety and Efficacy Study of CID-103 in Adults With Active and Chronic Active Renal Allograft Antibody Mediated Rejection.
Primary endpoint: Arms A: Number of participants experiencing study-specific safety events or meeting treatment stopping criteria
A Dose-escalation and Safety Study of CID-103 Followed by a Randomized, Open-label, Parallel-arm Multi-dose Study Evaluating the Efficacy and Tolerability of CID-103 in Adults With Chronic Immune Thrombocytopenia
Primary endpoint: Safety and tolerability of CID-103
Frequently asked questions
Who is developing cid-103?
cid-103 is being developed by CASI Pharmaceuticals, Inc (DE).
How many clinical trials involve cid-103?
BioSniper tracks 2 clinical trials involving cid-103.